spacer
home > epc > winter 2003 > alliances - a key source of industry value
PUBLICATIONS
European Pharmaceutical Contractor

Alliances - A Key Source of Industry Value

Collaborative alliances are now commonplace and increasingly core to companies' operations. In 2002, over 190 deals were signed each month and some 35 per cent of these required active collaboration between the parties. Despite their prominence, some two thirds of alliances fail to meet all or some of the collaborating partners' expectations. Alliance management has a vital role to play as organisations look to unlock maximum value from their collaborations now and in the future.

Alliance management is still a nascent competence within most organisations and there is, as yet, no industry norm for the organisation or role of alliance management. One reason for the diversity of alliance management structures and organisation is companies' continuing uncertainty about the optimum role that alliance management should perform - how does alliance management unlock maximum value from an organisation's portfolio of collaborations? Three questions may serve to clarify this:

1. What is alliance management's scope? To what extent is the alliance manager responsible for value creation, contract enforcement or asset protection?

2. Where should alliance management focus? Does the alliance manager concentrate solely on relational issues or does he have a responsibility for project/operational performance too?

3. What role should alliance management take? Should the alliance manager facilitate, coach and intervene operationally or monitor and control?

A recent seminar entitled 'Managing Pharmaceutical Alliances: Closing the Performance Gap', explored these and other issues. Thirty two delegates from pharmaceutical and biotechnology companies participated in a one day interactive event. This article covers some of the points that arose from the seminar.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Stuart Pavelin, Senior Director, Consultancy Group at PharmaVentures

Stuart Pavelin is a Senior Director for the Consultancy Group at PharmaVentures, a specialist health care consultancy focused on deals and deal making. He has spent the past decade working as a Management Consultant with pharmaceutical, biotechnology and other life sciences companies. In his work with these companies, Stuart has led international assignments covering corporate strategy, alliance management, product development strategy, performance management, process development and therapeutic/marketing strategy. He also serves as coach and mentor to some of his senior executive clients. Stuart holds an MBA from INSEAD, France, and a Masters degree from Imperial College of Science Technology and Medicine, London.

spacer
Stuart Pavelin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase AirBridgeCargo Airlines (ABC), one of the leaders in transportation of pharmaceutical products by air, and Zurich-based cold-chain ULD manufacturer SkyCell have sealed their partnership for the lease of all types of SkyCell containers to meet the demand for evolving volumes of passive pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019 YOY and demonstrated a two-fold increase.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement